4-Amino-3-Chlorophenol CAS 17609-80-2 Lenvatinib Mesylate Intermediate Purity >99.0% (HPLC)
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates ma maualuga mama
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Igoa Vailaau | 4-Amino-3-Chlorophenol |
Synonyms | 3-Chloro-4-Aminophenol;Lenvaint-G |
Numera CAS | 17609-80-2 |
CAT Numera | RF-PI1968 |
Tulaga Fa'asoa | I Fa'atauga, Oloa Fua e O'o i Tone |
Fuafua mole | C6H6ClNO |
Molecular Weight | 143.57 |
Malosi | 1.406±0.060g/cm3 |
Fa'ailoga | Ruifu Chemical |
Aitema | Fa'amatalaga |
Fa'aaliga | Enaena Uuta Malosi |
1 H NMR Alaleo | Osi ma le Fauga |
Fa'ailoa-HPLC | Ole taimi fa'atumauina e tutusa ma tulaga masani |
Mama / Suʻesuʻega Metotia | >99.0% (HPLC) |
Lisi Lisi | 138.0~141.0 ℃ |
Ma'imau ile Fa'amago | <1.00% |
Toega i luga o le mumu | <0.30% |
Aofa'i Fa'aleaga | <1.00% |
Tulaga Su'ega | Pisinisi Tulaga |
Fa'aoga | Intermediate o Lenvatinib Mesylate (CAS: 857890-39-2) |
afifi: Fagu, ato pepa alumini, 25kg/Kati Pusa, pe tusa ai ma manaoga o tagata faatau
Tulaga teuina:Teu i totonu o pusa faʻamaufaʻailoga i se nofoaga malulu ma mago;Puipui mai le malamalama ma le susu
4-Amino-3-Chlorophenol (CAS: 17609-80-2) o se vailaʻau taua tele, lea e faʻaaogaina lautele i le mamanu ma le tuʻufaʻatasia o anti-tumor, maʻi cardiovascular, faʻamaʻi faʻamaʻi faʻamaʻi.4-Amino-3-Chlorophenol o se mea taua tele i le sauniuniga o le Lenvatinib Mesylate (CAS: 857890-39-2).Na atiaʻe e Eisai Inc., lenvatinib mesylate o se vascular endothelial growth factor receptor (VEGF) inhibitor o loʻo i ai le gaioiga e faasaga i le VEGF subtypes 1, 2, ma le 3 ma na faʻatagaina e le FDA i le 2015 mo le togafitiga o le kanesa thyroid eseese lea e faʻapitonuʻu. faifai pea, metastatic, poʻo le alualu i luma ma e leʻi tali atu i togafitiga iodine radioactive.I le masina o Me 2016, na faʻamaonia ai e le FDA le vailaʻau e avea o se togafitiga faʻatasi ma everolimus mo le togafitiga o le gasegase o le tino.Talu ai ona o le VEGF (ma le fibroblast growth factor receptors, ua taʻua o FGFRs) e manatu e faia se sao i ala cardiovascular signaling, o le VEGF2R ma le FGFR inhibition o loʻo manatu o auala ia i tua atu o aʻafiaga muamua o le lenvatinib mesylate, o le toto maualuga.